A five-year early-stage study of high-intensity focused ultrasound resulted in tumour progression being halted in men with intermediate-risk, localised prostate cancer. But more evidence is needed to prove its benefits hold up against existing treatment options and for all men with the disease.
Preventing resistance to hormone therapy is a key goal for researchers trying to improve prostate cancer treatment. Now, research funded by us – thanks to your donations – has revealed that the immune system could have a part to play.
Across the papers today is news of a 'spit test' to help diagnose prostate cancer. It’s a promising step forward in genetics, but we still need better tests for diagnosis.
An early-stage trial of the immunotherapy drug, pembrolizumab, has proven it to be effective for a small number of men with incurable disease. We take a closer a look at how it works and what we're doing to bring the benefits of immunotherapy to many more men with prostate cancer.
New research backed by us and the Movember Foundation has shown that a type of ultrasound scan, which can detect the stiffness of the prostate, may be able to spot aggressive cancer.
An international group of researchers has identified dozens more genes that are potentially involved in the growth of prostate cancer. This could lead to new ways of treating the disease.
BLOG: After Theresa May’s announcement of £75 million for prostate cancer research, Ian le Guillou looks at how government and charity funding work together and how your support is critical to bag the big bucks needed for major breakthroughs.
A new research project, grant funded by us as part of our £2.7 million Research Innovation Awards scheme announced last month is trying to find new ways to stop cancer spreading to bones.
Evidence continues to mount for giving men an mpMRI scan before a prostate biopsy after an international trial of 500 men showed that mpMRI-guided biopsies help to catch more aggressive cancers and fewer harmless cancers.
With prostate cancer now the third biggest cancer killer, it is clearer than ever that we need big leaps forward. That’s why we’re awarding £2.7 million to UK scientists to fund some of the most exciting and revolutionary ideas.